As­traZeneca taps Al­teogen in deal worth more than $1.3B to make sub­cu­ta­neous can­cer drugs

As­traZeneca is bet­ting rough­ly $1.35 bil­lion on Ko­re­an biotech Al­teogen to help de­vel­op un­der-the-skin ver­sions of mul­ti­ple on­col­o­gy ther­a­pies.

The British phar­ma will li­cense ALT …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.